Enhertu Injection, Powder, Lyophilized, For Solution
Product Images NDC 65597-406

4 FDA label images from Daiichi Sankyo Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Enhertu (NDC 65597-406). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Daiichi Sankyo Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Enhertu 01)

Chemical Structure (Enhertu 01)
Chemical structure of fam-trastuzumab deruxtecan-nxki, showing its monoclonal antibody (mAb) linked via a linker to approximately eight deruxtecan molecules, the topoisomerase I inhibitor component.*
FDA Label Image

Figure 1 (Enhertu 02)

Figure 1 (Enhertu 02)
A Kaplan-Meier progression-free survival curve comparing Enhertu (fam-trastuzumab deruxtecan-nxki) versus ado-trastuzumab emtansine over 32 months. The y-axis shows progression-free survival percentage, and the x-axis shows time in months. The graph includes number at risk tables for both treatments.*
FDA Label Image

Principal Display Panel (100 mg Vial Carton)

Principal Display Panel (100 mg Vial Carton)
A Kaplan-Meier overall survival curve comparing Enhertu (fam-trastuzumab deruxtecan-nxki) versus Irinotecan or Paclitaxel over a 24-month period. The vertical axis represents overall survival percentage, and the horizontal axis shows time in months. The chart includes numbers at risk for both treatment groups at various time points.*
FDA Label Image

Enhertu 04

Enhertu 04
Packaging label for Enhertu injection, powder, lyophilized, for solution, 100 mg per vial. The label specifies the drug fam-trastuzumab deruxtecan-nxki, intended for intravenous infusion. It includes storage instructions to keep refrigerated, single-dose vial information, and mentions it is a hazardous drug. The labeler is Daiichi Sankyo Inc., co-marketed with AstraZeneca, with a Product NDC of 65597-406. Additional details include contents and reconstitution instructions.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.